Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 3, 2010, Pages 301-303

  Artunay, Ozgur ^a   Yuzbasioglu, Erdal ^a   Rasier, Rifat ^a   Sengul, Alper ^a   Bahcecioglu, Halil ^a  

^a ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MANNITOL; NICARDIPINE; PREDNISONE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BRAIN DISEASE; BRAIN EDEMA; CASE REPORT; ELECTROENCEPHALOGRAM; EPILEPSY; FLUORESCENCE ANGIOGRAPHY; HEADACHE; HUMAN; LETHARGY; MALE; MENINGITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RETINA EXAMINATION; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VOMITING; CHEMICALLY INDUCED; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; INJECTION; MACULAR DEGENERATION; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; VISUAL ACUITY; VITREOUS BODY;

EID: 77954200948     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0148     Document Type: Article

References (8)

1. Emerson, M.V., Lauer, A.K., Flaxel, C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 27 : 439-444, 2007.
2. Rosenfeld, P.J., Moshfeghi, A.A., and Puliafito, C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg. Lasers Imaging. 36 : 331-335, 2005.
3. Fung, A.E., Rosenfeld, P.J., and Reichel, E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90 : 1344-1349, 2006.
4. Willett, C.G., Boucher, Y., di Tomaso, E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10 : 145-147, 2004.
5. Oczan, C., Wong, S.J., and Hari, P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 9 : 980-982, 2006.
6. Bürki, F., Badie, K., Bartoli, P., et al. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br. J. Clin. Pharmacol. 65 : 793-794, 2008.
7. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114 : 855-859, 2007.
8. Rasier, R., Artunay, O., Yuzbasioglu, E., et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye. 23 : 1714-1718, 2009.